3D Vascular Network Assembly from hiPSCs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Diabetic patients with cardiovascular diseases face challenges in wound healing due to dysfunctional endothelial progenitor cells under hyperglycemia, and existing methods do not effectively derive functional vascular cells from Type 1 diabetes patient-derived human induced pluripotent stem cells (hiPSCs) for vascular therapy.
Innovation Solution
A method is developed to differentiate Type 1 diabetes patient-derived hiPSCs into early vascular cells (EVCs) that can mature into functional endothelial cells and form three-dimensional vascular networks in synthetic hyaluronic acid hydrogels, especially in response to hypoxic conditions, using a feeder-free differentiation protocol and Rho-associated coiled-coil kinase (ROCK) inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If endothelial progenitor cells are isolated and expanded from diabetic patients, then autologous vascular therapy can be provided, but the cell functionality is compromised under high glucose conditions leading to poor neovascularization
Solution Approach 1:
The patent creates a copy of healthy endothelial cells by reprogramming the patient's own somatic cells into induced pluripotent stem cells (iPSCs), which are then differentiated into healthy endothelial cells that are free from the effects of hyperglycemia. This copying approach allows diabetic patients to receive autologous therapy with functional cells despite their compromised endogenous progenitor cells.
Solution Approach 2:
The patent segments the vascular therapy process into distinct stages: (1) reprogramming somatic cells to iPSCs, (2) differentiating iPSCs into endothelial cells, (3) maturing cells in hypoxic conditions, and (4) encapsulating in hydrogel. This segmentation allows each stage to be optimized independently, ensuring high functionality of the final therapeutic cells.
2Productivity
If a step-wise differentiation scheme is used to generate early vascular cells from hiPSCs, then a bicellular population of EVCs can be produced, but the method did not determine if EVCs can be derived from Type 1 diabetes patient-derived hiPSCs
Solution Approach 1:
The patent modifies the differentiation parameters by introducing hypoxic conditions (low oxygen tension) during the maturation stage of EVCs. This parameter change significantly enhances the functionality and vascular network formation capability of EVCs derived from both healthy and diabetic hiPSCs, making the protocol universally applicable.
Solution Approach 2:
The patent develops a universal differentiation protocol that works for both healthy and Type 1 diabetic patient-derived hiPSCs. The same step-wise scheme involving ROCK inhibitor treatment, VEGF supplementation, and hypoxic maturation successfully generates functional EVCs from any hiPSC source, demonstrating broad applicability.
3Shape
If EVCs are encapsulated in synthetic hyaluronic acid hydrogel, then 3D vascular networks can form, but the ability to respond to hypoxic surroundings needs to be enhanced
Solution Approach 1:
The patent applies preliminary action by pre-maturing the EVCs in hypoxic conditions before encapsulation in the hydrogel. This preliminary exposure to hypoxia primes the cells to maintain their hypoxia-response capability and enhances their ability to form functional 3D vascular networks after encapsulation, ensuring reliable performance in the therapeutic application.
Data Source
AI summary
Early vascular cells (EVCs), including endothelial cells and pericytes, are generated from hiPSCs. Unlike the isolated endothelial progenitor cells, the differentiated ECs mature and are functional. When encapsulated in synthetic hydrogel, EVCs respond to matrix cues and self-assembled to form three-dimensional EVCs. Moreover, these EVCs respond to hypoxic microenvironment and undergo vasculogenesis to form complex 3D networks.